databases = {
    "Alzheimer": {
        "name": "Alzheimer",
        "examples": "\n   - 'MMSE: Mini-Mental State Examination'\n   - 'APOE4: Apolipoprotein E epsilon 4 allele'\n   - 'Beta-amyloid (CSF): Cerebrospinal fluid levels of beta-amyloid'",
        "shots": "1. Input record:\n   {'outcome_measurement_title': 'ADCS-ADL;\nRate of Change on CDR-SOB;\nNeuropsychiatric Inventory (NPI);\nRate of Change on the ADAS-Cog 11.;', 'outcome_measurement_description': 'ADCS-ADL = Alzheimer's Disease Cooperative Study Activities of Daily Living Score. This is a structured questionnaire about activities of daily living, administered to the subject's caregiver/study partner. The range of this instrument is 0 to 6 with lower numbers indicating greater impairment.;\nCDR-SOB = Clinical Dementia Rating, Sum of Boxes. This is a global rating of dementia severity based on the clinician's interpretation of the history and examination. The range of this instrument is 0 to 18 with higher numbers indicating greater impairment.;/nThe Neuropsychiatric Inventory quantifies behavioral changes in dementia, including depression, anxiety, psychosis, agitation, sleep change, appetite change, and others. This is a structured questionnaire administered to the subject's caregiver/study partner. The range of this instrument is 0 to 120 with higher numbers indicating greater impairment.;/nADAS-cog 11 = Alzheimer's Disease Assessment Scale, cognitive sub-scale in points per year. This is a psychometric measure sensitive to change in mild to moderate AD. The range of this instrument is 0 to 70 with higher numbers indicating greater impairment.;'}\n   Output:\n   {'analysis':'The record explicitly defines four clinical and neurpsychoogical assessment scales (ADCS-ADL, CDR-SOB, NPI, ADAS-Cog 11) whose global scores serve as quantifiable markers for clinical change assessment and each of them is specific for different cognitive domains, such as: i) cognitive functions (short- and long-term memory), ii) language (comprehension and expression), iii) orientation (awareness of time and place), iv) praxis (the ability to perform complex movements), v) Behavioral and Psychological Symptoms (delusions, hallucinations, mood disturbances - depression, anxiety, irritability, apathy, and euphoria -, agitation/aggression and disinhibition), vi) functional abilities (level of independence, self-care, instrumental activities)', 'biomarkers':['ADCS-ADL: Alzheimer's Disease Cooperative Study Activities of Daily Living Score','CDR-SOB: Clinical Dementia Rating Scale Sum of Boxes','NPI: Neuropsychiatric Inventory','ADAS-cog 11: Alzheimer's Disease Assessment Scale-Cognitive Subscale']}\n2. Input record:\n   {'outcome_measurement_title': 'Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 16 Weeks After Cessation of Study Drug;\nChange From Baseline in Neuropsychiatric Inventory (NPI) Score at 76 Weeks;\nChange From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks;\nChange From Baseline in Tau Concentration in Spinal Fluid up to 76 Weeks;\nLY450139 Population Pharmacokinetics: Clearance of LY450139;\nChange From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at 76 Weeks;\nChange From Baseline in Phosphorylated-Tau (P-Tau) Concentration in Spinal Fluid;\nChange From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 16 Weeks After Cessation of Study Drug;\nChange From Baseline in Positron Emission Tomography (PET) Using Fluorine-18 Fluorodeoxyglucose (18F-FDG) at 76 Weeks;\nChange From Baseline in Amyloid Imaging Positron Emission Tomography (AV-45 PET) up to 76 Weeks;\nChange From Baseline in Mini Mental State Examination (MMSE) Score at 76 Weeks;\nChange From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 76 Weeks;\nChange From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Inventory Score at 16 Weeks After Cessation of Study Drug;\nChange From Baseline in Hippocampal Volume Using Volumetric Magnetic Resonance Imaging (vMRI) up to 76 Weeks;\nChange From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 76 Weeks;\nChange From Baseline in Amyloid Beta (Aβ) 1-42 Concentration in Spinal Fluid up to 76 Weeks;\nLY450139 Population Pharmacokinetics: Volume of Distribution of LY450139;\nChange From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) Score at 16 Weeks After Cessation of Study Drug;\nPercent Change From Baseline in Amyloid Beta (Aβ) 1-42 Plasma Concentration at 52 Weeks;\nChange From Baseline in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score at 76 Weeks;\nChange From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) Score at 76 Weeks;\nChange From Baseline in Resource Utilization in Dementia-Lite (RUD-Lite) Score (Number of Hospitalizations) up to 76 Weeks;', 'outcome_measurement_description': 'ADAS-Cog11 consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.;\nNPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with the participant's behavior. Total score ranges from 12 to 144; Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.;\nADAS-Cog11 was used as a primary efficacy measure. It consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.;\nConcentration of total tau in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.;\nModel estimated apparent oral clearance. Clearance is defined as the volume of plasma that is completely cleared of drug (LY450139) per unit time.;\nCDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.;\nConcentration of p-tau in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.;\nADAS-Cog14 is ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, concomitant standard of care (SOC) medication.;\nMeasurement of local cerebral glucose metabolism by PET using the radioactive tracer 18F-FDG. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the Pons. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.;\nA radioactive tracer for PET that is a ligand for amyloid called AV-45. This permits the visualization of amyloid in the brains of Alzheimer's participants. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the cerebellar gray matter. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.;\nMMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, and ability to name objects, follow verbal and written commands, write a sentence, and copy figures) in elderly participants. The total score ranges from 0 to 30; Lower score indicates greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.;/nADCS-ADL is a 23-item inventory developed as a Rater-administered questionnaire answered by the participant's caregiver. It measures performance of basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.;/nThe vMRI assessment of left and right hippocampal volume is reported. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.;/nADAS-Cog12 is ADAS-Cog11 augmented with delayed free recall measure, resulting in a total score ranging from 0 to 80. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.;/nConcentration of an amino peptide known as Aβ 1-42 in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.;/nModel-estimated apparent volume of distribution. Volume of distribution is a measure of the extent to which the drug distributes in the body.;/nConcentration of amino acid peptide, known as Aβ 1-42, in plasma. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator.;/nEQ-5D (proxy version) measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression; each has 3 severity levels (no, some, severe problems) coded to a 1-digit number (1-3). Digits are combined into 5-digit number describing health state. Numerals 1-3 are not added for total score. VAS assesses caregiver's impression of participant's overall health state; scores range from 0 to 100; Lower scores indicate greater disease severity. Least Squares (LS) Mean value controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication.;/nAssesses healthcare resource utilization (formal and informal care). Information gathered on both caregivers (caregiving time, work status) and participants (accommodation and healthcare resource utilization) was collected from baseline and follow-up interviews; Reported number of hospitalizations per participant up to 76 weeks. Least Squares (LS) Mean value was controlled for age and investigator.;'}\n   Output:\n   {'analysis':'The record explicitly defines 22 markers covering: i) cognitive function with ADAS-Cog (11, 12, and 14 items), the Mini-Mental State Examination (MMSE), and the Clinical Dementia Rating (CDR-SB), ii) daily life abilities with ADCS-ADL, iii) behavioural symptoms with NPI, iv) biological markers with the assessment of the levels of tau, phosphorylated-tau (p-tau), and amyloid beta (Aβ) proteins in CSF or in blood plasma, v) brain imaging surrogate biomarkers, such as the change of the hippocampal volume via volumetric MRI scans as well as metabolic pattern changes in 18F-FDG PET and amyloid burden pattern changes in AV-45 PET images, vi) drug cleareance and drug volume distribution, vii) quality of life perception with EQ-5D, VAS and RUD-Lite scores','biomarkers':['ADAS-cog 11: Alzheimer's Disease Assessment Scale-Cognitive Subscale','ADAS-cog 12: Alzheimer's Disease Assessment Scale-Cognitive Subscale','ADAS-cog 14: Alzheimer's Disease Assessment Scale-Cognitive Subscale','CDR-SB: Clinical Dementia Rating Scale Sum of Boxes','NPI: Neuropsychiatric Inventory','Tau-CSF: Tau in CSF','P-Tau-CSF: Phosphorylated-Tau in CSF','Aβ-CSF: Amyloid Beta 1-42 in CSF','Aβ-Plasma: Amyloid Beta 1-42 in Plasma Blood','Drug-Clearance: Drug Clearance','Drug-Distribution Volume: Drug Distribution throughtout the Body','Change 18F-FDG PET: assessment of neuron metabolism change via PET','Change AV-45 PET: assessment of amyloid burder change via PET','Change Hippocampal Volume: assessment of neurodegeneration of the hippocampus','MMSE: Mini Metnal State Examination', 'ADCS-ADL: Alzheimer's Disease Cooperative Study Activities of Daily Living Score', 'EQ5D: EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy) Visual Analog Scale (VAS) Score', 'VAS: Visual Analog Scale', 'RUD-Lite: Resource Utilization in Dementia-Lite']}\n3. Input record:\n   {'outcome_measurement_title': 'Activities of Daily Living (ADCS-ADL);\nClinical Dementia Rating Scale-Sum of Boxes (CDR-SB);\nRegionally Averaged Cerebral Glucose Uptake Changes Measured by FDG PET Uptake With Voxel-based Method;\nFazekas Scale;\nAlzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog);\nMini-Mental State Examination (MMSE) in the Korean Version of the CERAD Assessment Packet)', 'outcome_measurement_description': 'The caregiver answered to the questions given to measure the cognitive function level of the patients in daily living. Lower scores indicate greater severity.\n23 questions Score Scale: 0-78 (min-MAX);\nMeasured by professionally trained clinicians. Higher score indicates more severe AD symptoms.\nScore Scale: 0-18 (min-MAX);\nRegional cerebral glucose uptake level was measured as the ratio value of FDG uptake of the each unit level to the global mean uptake value.;\nLevel of severity of white matter lesions in AD patients who can be legitimately administered with cilostazol. Measured by professionally trained clinicians.\nThe higher score indicates more severe white matter lesion. Max-min: 0-3;\nThe ADAS-Cog score is measured by the number of questions answered incorrectly, therefore the higher is the worse.\nScore Scale: 0-75 (min-MAX)\nEach subcategory scores are summed.\n1. Word-recall test (0-10)\n2. Commands (0-5)\n3. Constructional praxis (0-5)\n4. Naming Objects/ Fingers (0-5)\n5. Ideational Praxis (0-5)\n6. Orientation (0-8)\n7. Word Recognition (0-12)\n8. Remembering Test Instructions (0-5)\n9. Spoken Language Ability (0-5)\n10. Word Finding Difficulty (0-5)\n11. Comprehension (0-5);\nBasic cognitive functions are checked. (0-30) The score is better when higher.;'}\n   Output:\n   {'analysis':'The record explicitly defines 6 markers covering: i) cognitive function with Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Mini Mental State Examination (MMSE), Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB), ii) ability of the patient to perform daily life tasks (ADCS-ADL), iii) brain imaging surrogate biomarker and scale such as the change of the regionally averaged cerebral glucose uptake measured by voxel based morphometry (VBM) method in 18F-FDG PET images, and the Fazekas Scale to measures the severity of white matter lesions.','biomarkers':['ADCS-ADL: Alzheimer's Disease Cooperative Study Activities of Daily Living Score','CDR-SB: Clinical Dementia Rating Scale Sum of Boxes','ADAS-cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale','MMSE Korean Version of CERAD: Mini Mental State Examination','Fazekas: Fazekas Scale','Change 18F-FDG PET: assessment of neuron metabolism change via PET']}\n4. Input record:\n   {'outcome_measurement_title': 'Change From Baseline (Day 0) in Plasma Levels of Abeta42 and Abeta40 at Week 24;/nChange From Baseline (Day 0) in CSF Tau and Phosphorylated Tau (P-tau) Measures at Week 24;Change From Baseline (Day 0) in the Computerized Test Battery for Cognition (CogState) Battery Working Memory/Executive Function (WM/EF) Composite Score at Week 24;/nChange From Baseline (Day 0) in CSF Albumin Quotients at Week 24;/nChange From Baseline (Day 0) in Cerebral Spinal Fluid (CSF) Amyloid Beta Peptide (Abeta) 42 and Abeta40 at Week 24;/nChange From Baseline (Day 0) in Plasma Levels of Abeta42/Abeta40 Ratio at Week 24;/nChange From Baseline (Day 0) in CSF Abeta42/ Abeta40 Ratio at Week 24;/nPercentage Inhibition in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity at Week 24;/nChange From Baseline (Day 0) in CogState Battery Overall Composite Score;/nChange From Baseline (Day 0) in CogState Battery Attention Composite Score;', 'outcome_measurement_description': 'Plasma Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in plasma Abeta42 and Abeta40 are summarized. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.;/nCSF tau and P-tau were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in CSF tau and P-tau was summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.;/nThe WM/EF composite score was comprised of 5 functional tests including 1) Controlled oral word association which measured language fluency, planning and working memory, 2) Category naming: It measures semantic fluency, planning and working memory, 3) One-back: This is a measure of working memory. 4) Trail B: This is a measure of motor speed, visual scanning, and visual-motor integration. This test required attention and cognitive flexibility. 5) Go No-Go task: This test evaluate accuracy and reaction time for each response. The composite score calculated by standardizing the total score: sum of all responses obtained from these 5 functional test by using the formula (Total score of ITT population at baseline - Total score at Week 24) /standard deviation of mean total mean score at baseline. The observed composite score ranged from minimum -1.474 and maximum 1.596. Lower score means better cognitive status. Change from Baseline was calculated as post-dose visit minus Baseline value.;/nCSF albumin quotient was assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in albumin quotient is summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.;/nCSF Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in CSF Abeta42 and Abeta40 are summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.;/nPlasma Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in plasma Abeta42/Abeta40 ratio is summarized. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.;/nCSF Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in CSF Abeta42/Abeta40 ratio is summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.;/nPlasma Lp-PLA2 was assessed at Baseline visit (Day 0) and Week 24 (Day 168). Percentage inhibition in plasma Lp-PLA2 activity ratio is summarized. Percentage inhibition was calculated by dividing change from Baseline in plasma LpPLA2 by Baseline LpPLA2 multiplied by -100. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value.;/nCogState battery overall composite score comprised of 8 functional tests 1) Controlled oral word association test measured language fluency, planning and working memory. 2) Category naming test measured semantic fluency, planning and working memory. 3) One-back test measured working memory. 4) Trail B test measured motor speed, visual scanning and visual-motor integration, required attention and cognitive flexibility. 5) Go No-Go task evaluated accuracy and reaction time for each response. 6) International shopping list immediate and delayed recall tests measured episodic memory. 7) Identification task test assessed visual attention. 8) Trail A test measured psychomotor speed and attention. Composite score= total score (sum of all responses from 8 functional test) by formula (Total score at baseline - Week 24) / SD of total score at baseline. Score ranged: -1.070 to 0.907. Lower score indicated the better cognitive status. Change from Baseline= post-dose visit minus Baseline value;/nCogState battery attention composite score comprised of 2 functional tests including 1) Identification task test assessed visual attention and 2) Trail A test measured psychomotor speed and attention. Composite score calculated by standardizing the total score (sum of all responses from 2 functional test) by formula (Total score at baseline - Week 24) / SD of total score at baseline. The observed composite score ranged from minimum -1.756 and maximum 1.330. Higher score indicated the better attention. Baseline value was defined as the latest Day 0 value and Change from Baseline was calculated as post-dose visit minus Baseline value;'}\n   Output:\n   {'analysis':'The record explicitly defines XXX markers covering: i) cognitive function with the CogState battery (CogState) combined in 3 different composite scores, such as: a) the overall composite scores obtained with the combination of eight subtests to give a broad measure of overall cognitive change, b) the Working Memory/Executive Function (WM/EF) Composite Score to measure the patient's ability to plan, problem-solve, and manage multiple tasks, c) Attention Composite Score to to measure a person's visual attention and processing speed; ii) biological markers in Plasma (i.e.: levels of Aβ40, Aβ42, their ratio, Lipoprotein-associated Phospholipase A2 (Lp-PLA2) activity) or in CSF (i.e.: level of Tau, Phosphorylated Tau, Aβ40, Aβ42, Abeta42/Abeta40 Ratio, Albumin Quotient','biomarkers':['CogState Overall Score: CogState Battery','CogState Attention Score: CogState Battery','CogState Working Memory/Executive Function Score: CogState Battery', 'Tau-CSF: Tau in CSF','P-Tau-CSF: Phosphorylated-Tau in CSF','Aβ-CSF: Amyloid Beta 1-42 in CSF','Aβ-Plasma: Amyloid Beta 1-42 in Plasma Blood','Aβ-CSF: Amyloid Beta 1-40 in CSF','Aβ-Plasma: Amyloid Beta 1-40 in Plasma Blood', 'Albumin-CSF: Albumin Quotient', 'Lp-PLA2-Plasma: Lipoprotein-associated Phospholipase A2 activity']}"
    },
    "BPD": {
        "name": "BPD",
        "examples": "\n   - 'GAF: Global Assessment of Functioning Scale'\n   - 'TEAEs: Number of Treatment-emergent Adverse Events'\n   - 'BSL23: Abbreviated Borderline Symptom List'",
        "shots": "1. Input record:\n   {'outcome_measurement_title': 'Self-Report of Difficulties in Emotion Regulation (DERS);/nGroup x Time Interaction Amygdala Activity;', 'outcome_measurement_description': 'The present study examines DBT treatment effect on emotion regulation in unmedicated outpatients with BPD as measured by changes in the Difficulties in Emotion Regulation Scale. The DERS is a brief, 36-item, self-report questionnaire./nDERS total score ranges from 36- 180. Higher scores reflect higher difficulties in emotion regulation./nThe measure yields a total score as well as scores on six scales derived through factor analysis:/n1. Nonacceptance of emotional responses, 2. Difficulties engaging in goal directed behavior, 3. Impulse control difficulties, 4. Lack of emotional awareness, 5. Limited access to emotion regulation strategies, 6. Lack of emotional clarity Responses are on a 5-point scale: 1=almost never, 2=sometimes, 3=about half the time, 4=most of the time, 5=almost always;/n0 to 12 month difference scores in group x time interaction amygdala activity;'}\n   Output:\n   {'analysis':'The record explicitly defines two markers, the first is the self-reported questionnaire to measure the difficulties in emotion regulation scale (DERS); the second in the Amygdala activation assessed with fMRI EPI sequence to compare the group treated with Dialectical Behavior Therapy (DBT). The latter marker allow to measure how the amygdala activity of patients receiving DBT changed over 12 months, versus the activity of a control group (who did not receive the treatment). A significant 'interaction' would show that the DBT treatment had a specific effect on brain activity.', 'biomarkers':['DERS: Difficulties in Emotion Regulation Scale','Amygdala Activity: fMRI activation of amygdala']}\n2. Input record:\n   {'outcome_measurement_title': 'Borderline Evaluation of Severity Over Time (BEST);\nZanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD);\nMontgomery-Åsberg Depression Rating Scale (MADRS);\nBarratt Impulsiveness Scale (BIS);\nYoung Mania Rating Scale (YMS);\nSymptom Checklist -90-Revised (SCL-90-R);\nSheehan Disability Scale (SDS);\nOvert Aggression Scale - Modified (OAS-M);\nGlobal Assessment of Functioning Scale (GAF);', 'outcome_measurement_description': 'Scale including 15 items and three subscales. All items are rated on a Likert-like scale. A correction factor of 15 is added to yield the final score which can range from 12 (best) to 72 (worst).;\nThis is an assessment of change in DSM-IV borderline psychopathology. Consisting of nine criteria rated on a five-point anchored rating scale of 0 to 4, yielding a total score of 0 to 36. 0 being the best and 4 meaning the worse.;\nNine criteria rated on a six-point anchored rating scale of 0 to 6, yielding a total score of 0 to 60. O is the least and 6 is the highest. \n 0 to 6 - normal /symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression \>34 - severe depression.;\n30-item self-report questionnaire, that is scored to yield a total score, three second-order factors, and six first-order factors. patients rate the questions 1-4 1 being the least and 4 being the most.;\nEleven-item multiple choice diagnostic questionnaire, yielding total scores of 0-60. 0-4 rating 0-being least likely and 4 being most likely This scale assess manic symptoms;\n90 items measured on a Likert scale via self-report. Scale is 0-5 stating 0= strongly disagree and 5 is Strongly agree Measures psychological problems and symptoms;\nThree self-rated items, on a scale of 0-10. 0 is unimpaired 10 is highly impaired This measures functional impairment;\nFour part behavior rating scale designed to measure four types of aggressive behavior as witnessed in the past week. Each section consists of five questions. Total scores on the MOAS range from 0-40. 0 is the best and 40 is the worst of symptoms Reduction in scores shows a change of symptoms.;\nNumeric scale (1 through 100) used by mental health clinicians and physicians to rate subjectively the social, occupational, and psychological functioning of adults. 100 is the highest level of functioning. O is the least functional;'}\n   Output:\n   {'analysis':'The record explicitly defines 9 markers, the first is the Borderline Evaluation of Severity Over Time (BEST) to measure the overall BPD severity; the second is the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD); the third is Montgomery-Åsberg Depression Rating Scale (MADRS) that is a scale for measuring the severity of depression; the fourth is represented by Young Mania Rating Scale (YMS) to assess manic symptoms; the fifth is Barratt Impulsiveness Scale (BIS) a self-report questionnaire that measures impulsiveness; the sixth is Overt Aggression Scale - Modified (OAS-M) to measure the severity and frequency of aggressive behavior; the seventh is the Global Assessment of Functioning Scale (GAF) a rating scale to assess a person's social, occupational, and psychological functioning; the eight is Sheehan Disability Scale (SDS) that is a self-rated scale that measures a person's level of functional impairment in three areas (work, social life, and family life); the nineth is the Symptom Checklist -90-Revised (SCL-90-R) that is a broad self-report questionnaire that measures a wide range of psychological problems and symptoms', 'biomarkers':['BEST: Borderline Evaluation of Severity Over Time','ZAN-BPD: Zanarini Rating Scale for Borderline Personality Disorder','MADRS: Montgomery-Åsberg Depression Rating Scale','YMS: Young Mania Rating Scale','BIS: Barratt Impulsiveness Scale','OAS-M: Overt Aggression Scale - Modified ','GAF: Global Assessment of Functioning Scale','SDS: Sheehan Disability Scale','SCL-90-R: Symptom Checklist -90-Revised']}\n3. Input record:\n   {'outcome_measurement_title': 'Symptom Change - SCL-90-R;/nSymptom Change - BPDSI Subscales;/nMetacognitive Capacity;/nSymptom Change - CGI-I;/nSymptom Change - BPRS;/nSymptom Change - Borderline Checklist;/nLevels of Cortisol;/nNumber of Participants With Possibly and Probably Related Adverse Events;/nSymptom Change - CGI-S;/nRapid Symptom Change;/nDurable Symptom Change;', 'outcome_measurement_description': 'The Symptom Checklist-90-Revised (SCL-90-R) instrument helps evaluate a broad range of psychological problems and symptoms of psychopathology. The instrument is also useful in measuring patient progress or treatment outcomes. The SCL-90-R contains 90 items on a 5-point rating scale, with a higher score indicating more severity. The items are categorized into 12 domains (9 scores along primary symptom dimensions and 3 scores among global distress indices). A t-score for each domain is then obtained by norming by sex and ranges between 19-81, with a higher score indicating more severity.;/nBorderline Personality Disorder Severity Index (BPDSI) symptom domain subscales scores. The BPDSI is a semi-structured clinical interview assessing the frequency and severity of manifestations of Borderline Personality Disorder (BPD) during a circumscribed period of the previous 7 days. The BPDSI measures 9 symptoms associated with BPD on a Likert scale ranging from 0-7 (0 = never; 7 = daily). Each symptom measure produces a mean score ranging from 0-7, with a higher score indicating more prevalent symptoms.;/nThe Indiana Psychiatric Illness Interview (IPII) is a semi-structured interview developed to assess illness narratives. Responses are audio taped and later transcribed. It is scored using the Metacognition Assessment Scale- Abbreviated (MAS-A), which has four domains of metacognition: i) Self-Reflectivity ranging from 0-9; ii) Understanding the Mind of Other ranging from 0-7; iii) Decentration ranging from 0-3; and iv) Mastery ranging from 0-9. Lower scores indicate metacognitive deficits, higher scores indicate more integrated and nuanced metacognition. MAS-A total score is the sum of the scores on each of the domains of metacognition, ranging from 0-28, with a lower score indicating metacognitive deficits and a higher score indicating more integrated and nuanced metacognition.;/nThe Clinical Global Impressions Improvement (CGI-I) scale is used to assess the clinical change as compared to symptoms at baseline using a 7-point Likert scale, ranging from very much improved (1) to very much worse (7), with a higher score indicating more severity.;/nThe Brief Psychiatric Rating Scale (BPRS) is an 19-item scale measuring positive symptoms, general psychopathology and affective symptoms during the last 7 days. The BPRS measures symptoms with scores ranging from 0-7, with a higher score indicating more severity. A total score is then calculated by adding all the item scores, ranging from 0-133, with a higher score indicating more severity.;/nThe Borderline Personality Checklist (BPD Checklist) is a 47-item DSM-IV based self-report questionnaire, designed to assess the experienced burden of specific BPD symptoms during the previous week. The BPD Checklist measures symptoms with scores ranging from 1-5, with a higher score indicating more severity. A total score is then calculated by adding all the item scores, ranging from 47-235, with a higher score indicating more severity.;/nThe Indiana Psychiatric Illness Interview (IPII) is a semi-structured interview developed to assess illness narratives. Responses are audio taped and later transcribed. It is scored using the Metacognition Assessment Scale- Abbreviated (MAS-A), which has four domains of metacognition: i) Self-Reflectivity ranging from 0-9; ii) Understanding the Mind of Other ranging from 0-7; iii) Decentration ranging from 0-3; and iv) Mastery ranging from 0-9. Lower scores indicate metacognitive deficits, higher scores indicate more integrated and nuanced metacognition. MAS-A total score is the sum of the scores on each of the domains of metacognition, ranging from 0-28, with a lower score indicating metacognitive deficits and a higher score indicating more integrated and nuanced metacognition'}\n   Output:\n   {'analysis':'The record explicitly defines nine markers that are related to how the patients' psychological symptoms change and how biological markers evolve. The first marker is represented by Symptom Checklist-90-Revised (SCL-90-R) that evaluates a wide range of psychological issues and symptoms; the second and third are the Clinical Global Impressions - Improvement & Severity (CGI-I & CGI-S) that are scales that subjectively assess how much a patient's condition has improved or worsened, and the overall severity of their symptoms; the forth is the Brief Psychiatric Rating Scale (BPRS); the fifth is the Borderline Personality Disorder Severity Index (BPDSI) a semi-structured interview that measures the frequency and severity of the symptoms of BPD; the sixth is the Borderline Checklist a self-report questionnaire of 47 items assessing the burden of specific BPD symptoms according to DSM-IV; the seventh is the Metacognition Assessment Scale (MAS-A) that represents the capacity to understand for the patient's its own mental states and those of others; the eight is a biological marker represented by the Cortisol Level that is a stress hormone and is used to understand how the patient's body is responding to stress and whether the treatment is having a physiological effect; the nineth is represented by the number of adverse event from the treatment.', 'biomarkers':['SCL-90-R: Symptom Checklist-90-Revised','CGI-I: Clinical Global Impressions - Improvement','CGI-S: Clinical Global Impressions - Severity','BPRS: Brief Psychiatric Rating Scale','BPDSI: Borderline Personality Disorder Severity Index','BPD-Checklist: 47-item Borderline Checklist','MAS-A: Metacognition Assessment Scale', 'Cortisol: Cortisol level','TEAEs: Number of Treatment-emergent Adverse Events']}\n4. Input record:\n   {'outcome_measurement_title': 'Change From Baseline in Simpson-Angus Scale (SAS) Total Score;/nChange From Baseline in Body Mass Index (BMI);/nChange From Baseline in Barnes Akathisia Rating Scale (BARS): Global Clinical Assessment of Akathisia Score;/nNumber of Participants With Suicidal Behavior and Suicidal Ideation As Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS);/nChange From Baseline in the Patient's Global Impression of Severity (PGI-S);/nClinical Global Impression - Improvement (CGI-I) Scale Score;/nChange From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score;/nNumber of Participants With Potentially Clinically Relevant Abnormalities in Vital Signs;/nNumber of Participants With Potential Clinical Relevant Laboratory Test Values - Prolactin;/nChange From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score;/nNumber of Participants With Potentially Clinically Relevant Laboratory Test Values;/nNumber of Participants With Potentially Clinically Relevant Abnormalities in 12-Lead Electrocardiogram (ECG) Parameters;/nChange From Baseline in the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) Total Score;/nPatient's Global Impression of Change (PGI-C) Scale Score;Number of Participants With Treatment Emergent Adverse Events (TEAEs);', 'outcome_measurement_description': 'The SAS consisted of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item was rated on a 5-point scale, with a score of zero representing the absence of symptoms and a score of 4 representing a severe condition. The SAS total score was the sum of the scores for all 10 items and ranged from 0 to 40. Higher scores indicated worst outcome.;/nBMI is defined as weight in kilograms divided by the square of height in meters.;/nThe BARS consisted of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The global clinical evaluation was made on a 6-point scale, with zero representing absence of symptoms and a score of 5 representing severe akathisia.;/nSuicidality was monitored using the C-SSRS. Suicidality was defined as at least one occurrence of suicidal ideation (including wish to be dead, non-specific suicidal thought, suicidal ideation-no intent, ideation with intent, no plan, ideation with plan/intent) or at least one occurrence of suicidal behavior (actual attempt, non-suicidal self-injurious behavior, interrupted attempt, aborted attempt, preparatory acts/behavior, suicidal behavior) for the assessment period.;/nPGI-S is a 7-point single-item self-report scale for the participant to rate the severity of symptoms of BPD ranging from 0 to 7 where 1 denoted no symptoms and 7 denoted very severe.;/nParticipant's condition was assessed using CGI-I scale. CGI-I is an observer-rated scale with a total score of 0 to 7 and a higher score represents a worse outcome. The score included the following response choices: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.;/nThe severity of illness for each participant was rated using the CGI-S. CGI-S is an observer-rated scale with a total score range of 0 to 7 where a higher score represented a worse outcome. The response choices were 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.;/nVital Signs included orthostatic hypotension, heart rate (HR), systolic and diastolic blood pressure (bp), and weight. Potential clinical relevance criterion: Orthostatic Hypotension:\>= 20 millimeters of mercury (mmhg) decrease in systolic bp and \>= 25 beats per minute (bpm) increase in HR from supine to standing; HR Standing (bpm):\< 50 and decrease \>= 15,\> 120 and increase \>= 15; HR Supine (bpm): \< 50 and decrease \>= 15,\>120 and increase \>= 15; Systolic BP Standing (mmhg):\< 90 and decrease \>=20,\> 180 and increase \>= 20; Systolic BP Supine (mmhg):\< 90 and decrease \>= 20, \>180 and increase \>= 20; Diastolic BP Standing (mmHg): \< 50 and decrease \>= 15,\> 105 and increase \>= 15; Diastolic BP Supine (mmHg):\< 50 and decrease \>= 15, \> 105 and increase \>= 15; Weight (kilograms\[kg\]): Decrease or increase \>= 7%. Only those categories with at least one participant with event are reported.;/nNew onset (\> 1 x upper limit of normal {ULN}, \> 2 x ULN, 3 X ULN) prolactin means a participant who attains a categorical change during treatment phase but not at baseline. Only those categories with at least one participant with event are reported.;/nAIMS assessment consisted of 10 items describing symptoms of dyskinesia (muscles of facial expression, lips and perioral area, jaw, tongue, upper extremities, lower extremities, neck/shoulders/hips, overall movement severity, incapacitation, participant awareness). Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7) were observed unobtrusively while participant was at rest (e.g., in waiting room), and study physician would make global judgments on participant's dyskinesia's (items 8 through 10). Each item was rated on 5-point scale of severity from 0 (none) to 4 (severe) and assessment of problems with teeth or dentures (yes = 1, no = 0) and if the participant normally wears dentures (yes = 1, no = 0). Total score ranged from 0 to 42. Higher scores indicated worst outcome.;/nLaboratory parameters included hematology(Hem), serum chemistry(Che) and urinalysis(Uri). Criterion:Che-Alkaline Phosphatase (Units/liter \[U/L\]):≥3 x ULN, Aspartate Aminotransferase (U/L):≥3 x ULN,Bilirubin (mg/deciliter\[dL\]):≥2.0,Cholesterol(Cho); Cho,fasting(mg/dl):≥240,Creatine Kinase(U/L):≥3 x ULN, Creatinine(mg/dL):≥2.0,Glucose (Glu);Glu,fasting(mg/dL):100,High Density Lipoprotein (HDL) Cho (mg/dL):Male (M) < 40or Female (F) <50, Low Density Lipoprotein (LDL) Cho(mg/dL):≥160,Prolactin (nanograms/milliliter [ng/mL]):>1 x ULN,Triglyceride (mg/dL):≥150,Urate(mg/dL): M ≥10.5 or F ≥8.5,Urea Nitrogen (mg/dL):≥30,Hem-Eosinophils (Eosi) (10^9 L):≥10%,Hematocrit (%): M ≤37% and ≥3 percentage (per) point decrease from baseline or F≤32% and ≥3per point decrease from baseline, Hemaglobin(gram per deciliter [g/dL]):M ≤11.5 or F ≤9.5,Leukocytes(10^9/L):≤2.8 x10^3/uL,≤16.0 x10^3/uL,Platelets(10^9/L):≤75 x10^3/ uL,≥700 x10^3/uL,Uri-Glu,urine; Protein,urine:Increase of ≥2U.'}\n   Output:\n   {'analysis':'The record explicitly defines multiple markers related to treatment effectiveness, movement-related side effects, and lab tests to monitor physical health and detect any adverse effect. The first marker related to treatment assessment is represented by Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) that allows to measure the severity of BPD symptoms; other two markers are the Patient's Global Impression of Severity (PGI-S) and the Patient's Global Impression of Change (PGI-C) that are self-reported scales where participants rate the severity of their illness and the overall change they experience; other similar markers are the Clinical Global Impressions - Improvement & Severity (CGI-I & CGI-S) that are completed by the clinician to provide an objective assessment of the patient's symptom severity and improvement; Columbia-Suicide Severity Rating Scale (C-SSRS) is a behavioural marker to assess the suicidal ideation; another marker is the Abnormal Involuntary Movement Scale (AIMS) that measures the severity of involuntary movements (dyskinesia) in various body parts; Simpson-Angus Scale (SAS) represents another movement related marker assessing symptoms of Parkinsonism like tremors and rigidity; Barnes Akathisia Rating Scale (BARS) measures akathisia, which is a feeling of inner restlessness and an inability to stay still; another biological marker is represented by the number of heart-rate abnornalities including Bradycardia, Sinus bradycardia, symmetrical T-wave inversion post baseline or other events assessed via Electrocardiogram (ECG); change in Body Mass Index (BMI); change of the Blood and Urine  tests to check for abnormal values in a wide range of parameters, liver function (AST, Alkaline Phosphatase), kidney function (Creatinine), substances like prolactin, which is affected by psychotropic drugs; the number of adverse event from the treatment', 'biomarkers':['ZAN-BPD: Zanarini Rating Scale for Borderline Personality Disorder', 'PGI-S: Patient's Global Impression of Change Score', 'PGI-C: Patient's Global Impression of Change Score', CGI-I: Clinical Global Impressions - Improvement','CGI-S: Clinical Global Impressions - Severity', 'C-SSRS: Columbia-Suicide Severity Rating Scale', 'AIMS: Abnormal Involuntary Movement Scale', 'SAS: Simpson-Angus Scale', 'BARS: Barnes Akathisia Rating Scale', 'HR-abnormality: number of heart-rate abnornalities', 'Lab-Tests: Body Mass Index (BMI), Blood and Urine parameters', 'TEAEs: Number of Treatment-emergent Adverse Events']}"
    },
    "CN": {
        "name": "system prompt for CNV",
        "examples": "user prompt for CNV",
        "shots": ""
    },
    "Depression": {
        "name": "system prompt for depression",
        "examples": "user prompt for depression",
        "shots": ""
    },
    "Dermatitis": {
        "name": "system prompt for dermatitis",
        "examples": "user prompt for dermatitis",
        "shots": ""
    },
    "Diabete": {
        "name": "system prompt for diabetes",
        "examples": "user prompt for diabetes",
        "shots": ""
    },
    "HT": {
        "name": "system prompt for hypertension",
        "examples": "user prompt for hypertension",
        "shots": ""
    },
    "Hypertension": {
        "name": "system prompt for hypertension",
        "examples": "user prompt for hypertension",
        "shots": ""
    },
    "KT": {
        "name": "system prompt for kidney transplant",
        "examples": "user prompt for kidney transplant",
        "shots": ""
    },
    "LT": {
        "name": "system prompt for liver transplant",
        "examples": "user prompt for liver transplant",
        "shots": ""
    },
    "MS": {
        "name": "system prompt for multiple sclerosis",
        "examples": "user prompt for multiple sclerosis",
        "shots": ""
    },
    "Partial_Seizure": {
        "name": "system prompt for partial seizure",
        "examples": "user prompt for partial seizure",
        "shots": ""
    },
    "PS00": {
        "name": "system prompt for PS00",
        "examples": "user prompt for PS00",
        "shots": ""
    },
    "PSO01": {
        "name": "system prompt for PSO01",
        "examples": "user prompt for PSO01",
        "shots": ""
    },
    "PSO02": {
        "name": "system prompt for PSO02",
        "examples": "user prompt for PSO02",
        "shots": ""
    },
    "Schizophrenia": {
        "name": "system prompt for schizophrenia",
        "examples": "user prompt for schizophrenia",
        "shots": ""
    },
    "Sclerosis": {
        "name": "system prompt for sclerosis",
        "examples": "user prompt for sclerosis",
        "shots": ""
    }
}

databases_list = ["Alzheimer", "Bipolar", "BPD", "CN", "Depression", "Dermatitis", "Diabete", "HT", "Hypertension", "KT", "LT", "MS", "Partial_Seizure", "PS00", "PSO01", "PSO02", "Schizophrenia", "Sclerosis"]

def get_prompt(dataset_type: str):
    """
    Restituisce il prompt di sistema e utente per il dataset specificato.
    
    Args:
        dataset_type (str): Tipo di dataset (es. "Alzheimer", "Bipolar", etc.)
        
    Returns:
        Tuple[str, str]: Prompt di sistema e utente
    """
    if dataset_type in databases:
        return databases[dataset_type]["name"], databases[dataset_type]["examples"], databases[dataset_type]["shots"]
    else:
        raise ValueError(f"Dataset {dataset_type} non supportato.")

